Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 versus investigator's choice in recurrent or metastatic nasopharyngeal carcinoma
2015-000454-38Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of spartalizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Jan 2016; status: completed.
02
Drugs
spartalizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on 2015-000454-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000454-38.